News | June 21, 2026
Evonik sells Hanau pharma assets to ProChem in strategic portfolio shift
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
Evonik researchers say they have achieved a significant breakthrough with Ecobiol
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Ultra-high purity surfactant for biologics and parenteral drug formulations
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The company’s largest center for medical device applications, serving the entire Asian market
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
Increases speed to market for drug developers working on nucleic acid therapeutics
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
